Regeneron Pharmaceuticals Inc (REGN)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account

Sell

$704.00

Buy

$743.50

arrow-down$-5.51 (-0.74%)

Prices updated at 13 Dec 2025, 00:51 EST

Prices minimum 15 mins delay

Prices in USD

Regeneron Pharmaceuticals Inc is an integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

NASDAQ

-1.69%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Dr. George D. Yancopoulos,M.D.,PhD

CEO

Dr. Leonard S. Schleifer,M.D.,PhD

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

15,207

Head office

777 Old Saw Mill River Road

Tarrytown

United States

10591-6707

+1 914 847-7000

manisha.narasimhan@regeneron.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Arthur Frederick Ryan Independent Director	0.12m
Dr. Leonard S. Schleifer,M.D.,PhD Co-Chairman of the Board, Co-President and Chief Executive Officer	1.94m
Dr. Joseph L. Goldstein,M.D. Independent Director	0.11m
Dr. N. Anthony Coles, M.D. Independent Director	0.10m
Dr. Michael S. Brown, M.D. Independent Director	0.12m
Dr. Craig B. Thompson,M.D. Independent Director	0.10m
Ms. Christine A. Poon Lead Independent Director	0.17m
Dr. George D. Yancopoulos,M.D.,PhD Co-Chairman of the Board, Co-President and Chief Scientific Officer	1.94m
Mr. George L. Sing Independent Director	0.12m
Mr. Joseph J. Larosa Executive Vice President, General Counsel and Secretary	-
Mr. Daniel P. Van Plew Executive Vice President and General Manager, Industrial Operations and Product Supply	0.96m
Dr. David P. Schenkein, M.D. Independent Director	0.10m
Dr. Bonnie L. Bassler, PhD Independent Director	0.11m
Ms. Marion McCourt Executive Vice President, Commercial	-
Dr. Huda Y. Zoghbi, M.D. Independent Director	0.11m
Mr. Christopher R. Fenimore Executive Vice President, Finance and Chief Financial Officer	0.66m
Mr. Andrew J Murphy Executive Vice President, Research	0.80m
Ms. Kathryn Guarini, PhD Independent Director	0.10m
Mr. Jason Pitofsky Principal Accounting Officer, Vice President and Controller	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Vanguard Group Inc	9,424,048
BlackRock Inc	8,837,174
JPMorgan Chase & Co	8,144,652
State Street Corp	4,691,223
Dodge & Cox	4,550,845

Director dealings

Date chevron-l-regular chevron-r-regular	Action
31 Dec 2024	-
02 Jan 2025	-
31 Dec 2024	-
02 Jan 2025	-
31 Dec 2024	-
16 Dec 2024	-
16 Dec 2024	-
16 Dec 2024	-
16 Dec 2024	-
16 Dec 2024	-
16 Dec 2024	-
16 Dec 2024	-
09 Dec 2024	-
06 Dec 2024	-
09 Dec 2024	-
06 Dec 2024	-
06 Dec 2024	-
09 Dec 2024	-
06 Dec 2024	-
06 Dec 2024	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.